NCT00100074Unknown1 期
Safety and Tolerability Study of Sublingual Lobeline
适应症
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 8
- 试验地点
- 2
- 主要终点
- Safety
研究概览
简要总结
To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.
详细描述
The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.
研究设计
- 研究类型
- Interventional
- 主要目的
- Diagnostic
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy individuals with a body mass index between 18 and
- •Willing and able to give written consent.
- •Must have a negative drug test
- •Females must have a negative pregnancy test prior to study drug administration
- •Must have no medical contraindications as determined by routine testing
排除标准
- •Please contact the site for more information
结局指标
主要结局
Safety
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1Methamphetamine DependenceNCT00519259National Institute on Drug Abuse (NIDA)12
已完成
1 期
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen ExtractsHouse Dust Mite AllergyAsthmaNCT01608243Stallergenes Greer94
已完成
1 期
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in AdolescentsNCT01919554Stallergenes Greer37
已完成
1 期
Safety and the Efficacy of a Sublingual Administration of Flumazenil to Reverse the Effect of Hypnotic Drugs in Healthy AdultsHealthyNCT01071889Coeruleus Ltd.10
终止
3 期
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)Major Depressive DisorderNCT01156415Novartis Pharmaceuticals837